Please try another search
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
Name | Age | Since | Title |
---|---|---|---|
Helmut W. Jeggle | 53 | 2008 | Independent Member of Supervisory Board |
Helga Rübsamen-Schaeff | 74 | 2015 | Independent Member of Supervisory Board |
Manfred Rüdiger | 59 | 2005 | Independent Deputy Chairman of Supervisory Board |
Wolff Schmiegel | - | - | Member International Scientific Expert Panel |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review